Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
de Boer, Richard H Arrieta, Óscar Yang, Chih-Hsin Gottfried, Maya Chan, Valorie Raats, Johann de Marinis, Filippo Abratt, Raymond P Wolf, Jürgen Blackhall, Fiona H
de Boer, Richard H
Arrieta, Óscar
Yang, Chih-Hsin
Gottfried, Maya
Chan, Valorie
Raats, Johann
de Marinis, Filippo
Abratt, Raymond P
Wolf, Jürgen
Blackhall, Fiona H
Citations
Altmetric:
Abstract
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed as second-line therapy in advanced non-small-cell lung cancer.
Affiliation
Description
Date
2011-03-10
Publisher
Collections
Keywords
Type
Article
Citation
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. 2011, 29 (8):1067-74 J. Clin. Oncol.